{"id":"ts-1-s-1","safety":{"commonSideEffects":[{"rate":"40-50","effect":"Nausea and vomiting"},{"rate":"30-40","effect":"Diarrhea"},{"rate":"30-40","effect":"Anorexia"},{"rate":"20-30","effect":"Bone marrow suppression (leukopenia, thrombocytopenia)"},{"rate":"10-20","effect":"Stomatitis"},{"rate":"5-15","effect":"Hand-foot syndrome"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"S-1 is a fixed-dose combination of tegafur (a prodrug of 5-fluorouracil), gimeracil (a dihydropyrimidine dehydrogenase inhibitor), and oteracil (a orotate phosphoribosyltransferase inhibitor). This combination enhances 5-FU bioavailability and reduces gastrointestinal toxicity by modulating fluoropyrimidine metabolism. It acts as an antimetabolite, primarily targeting thymidylate synthase to disrupt DNA synthesis in rapidly dividing cancer cells.","oneSentence":"TS-1 (S-1) is an oral fluoropyrimidine combination that inhibits thymidylate synthase and other enzymes in the pyrimidine synthesis pathway to suppress tumor cell DNA synthesis.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:50:58.036Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Gastric cancer"},{"name":"Colorectal cancer"},{"name":"Pancreatic cancer"},{"name":"Biliary tract cancer"}]},"trialDetails":[{"nctId":"NCT07182565","phase":"PHASE1, PHASE2","title":"Hypofractionated Radiotherapy Plus Immunochemotherapy for Neoadjuvant Treatment of Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"West China Hospital","startDate":"2025-11-18","conditions":"Gastroesophageal Junction Adenocarcinoma, Hypofractionated Radiotherapy","enrollment":84},{"nctId":"NCT04172402","phase":"PHASE2","title":"NGS as the First-line Treatment in Advanced Biliary Tract Cancer","status":"COMPLETED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2019-12-27","conditions":"Advanced Biliary Tract Cancer","enrollment":48},{"nctId":"NCT01286766","phase":"PHASE2","title":"Neoadjuvant Combination Chemotherapy of DCS and DCF in Patients With Locally Advanced Gastric Adenocarcinoma","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2009-09","conditions":"Gastric Cancer","enrollment":6},{"nctId":"NCT03814759","phase":"PHASE2","title":"Preoperative Chemoradiotherapy for Locally Advanced Resectable Gastric Adenocarcinoma","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2016-12-12","conditions":"Gastric Adenocarcinoma","enrollment":102},{"nctId":"NCT01285557","phase":"PHASE3","title":"Diffuse Gastric and Esophagogastric Junction Cancer S-1 Trial","status":"TERMINATED","sponsor":"Taiho Oncology, Inc.","startDate":"2011-04-14","conditions":"Metastatic Diffuse Gastric Cancer Including Carcinoma of the Gastro-esophageal Junction","enrollment":361},{"nctId":"NCT05955157","phase":"PHASE2, PHASE3","title":"Combined S-1 With DC+CIK As Maintenance Therapy For Advanced Pancreatic Ductal Adenocarcinoma","status":"UNKNOWN","sponsor":"University of Malaya","startDate":"2023-01-03","conditions":"Pancreatic Ductal Adenocarcinoma, Advanced Solid Tumor","enrollment":52},{"nctId":"NCT04999332","phase":"PHASE2","title":"Perioperative Leucovorin, Oxaliplatin, Docetaxel and S-1 (LOTS) For Locally Advanced Gastric or Gastroesophageal Junction Cancer","status":"UNKNOWN","sponsor":"National Cheng-Kung University Hospital","startDate":"2021-12-10","conditions":"Gastric Cancer, Gastric Adenocarcinoma, Effects of Chemotherapy","enrollment":58},{"nctId":"NCT03726021","phase":"PHASE2","title":"Study of Irinotecan,Oxaliplatin, and S1 in Patients With Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Qingdao Central Hospital","startDate":"2018-01-26","conditions":"Overall Survival","enrollment":47},{"nctId":"NCT02191566","phase":"PHASE2","title":"S-1/Oxaliplatin for High Risk Patients Who Underwent Gastrectomy","status":"TERMINATED","sponsor":"Kangbuk Samsung Hospital","startDate":"2015-05","conditions":"Stomach Cancer","enrollment":8},{"nctId":"NCT03559348","phase":"PHASE2","title":"Locally Advanced or Metastatic Pancreatic Adenocarcinoma","status":"COMPLETED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2018-04-03","conditions":"Pancreatic Adenocarcinoma","enrollment":49},{"nctId":"NCT00429858","phase":"PHASE2","title":"Gemcitabine and S-1 for Locally Advanced Unresectable or Metastatic Pancreatic Cancer","status":"TERMINATED","sponsor":"Andrew Ko","startDate":"2007-01-22","conditions":"Pancreatic Cancer","enrollment":21},{"nctId":"NCT01761461","phase":"PHASE3","title":"Phase III Randomized Trial of Adjuvant Chemotherapy With S-1 vs S-1/Oxaliplatin ± Radiotherapy for Completely Resected Gastric Adenocarcinoma : The ARTIST II Trial","status":"UNKNOWN","sponsor":"Samsung Medical Center","startDate":"2013-02-06","conditions":"Gastric Cancer","enrollment":547},{"nctId":"NCT00915382","phase":"PHASE3","title":"Trial of 3-weekly Versus 5-weekly Schedule of S-1 Plus Cisplatin in Gastric Cancer: SOS","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2009-01","conditions":"Advanced Gastric Cancer","enrollment":625},{"nctId":"NCT02301481","phase":"PHASE2","title":"A Randomized Phase II Trial of Neoadjuvant Chemotherapy Compared With Chemoradiotherapy in Gastric Adenocarcinoma","status":"COMPLETED","sponsor":"Chinese Academy of Medical Sciences","startDate":"2014-01","conditions":"Stomach Neoplasms, Neoadjuvant Therapy, Chemoradiotherapy","enrollment":71},{"nctId":"NCT02425137","phase":"PHASE2","title":"A Study of S-1 in Combination With Gemcitabine as First-Line Treatment in Patients With Advanced Biliary Tract Cancer","status":"COMPLETED","sponsor":"TTY Biopharm","startDate":"2015-04","conditions":"Advanced Biliary Tract Cancer(BTC)","enrollment":51},{"nctId":"NCT02182778","phase":"PHASE3","title":"GEM/Cisplatin/S-1 vs GEM/Cisplatin for Biliary Tract Cancer","status":"COMPLETED","sponsor":"Kansai Hepatobiliary Oncology Group","startDate":"2014-07-09","conditions":"Biliary Tract Cancer","enrollment":246},{"nctId":"NCT01821248","phase":"PHASE2","title":"A Phase II Trial of Preoperative Chemotherapy for Biliary Tract Cancer (BTC) With Node Metastasis","status":"UNKNOWN","sponsor":"Kansai Hepatobiliary Oncology Group","startDate":"2013-07-23","conditions":"Biliary Tract Cancer","enrollment":25},{"nctId":"NCT01283204","phase":"PHASE2","title":"Trial of 4-regimen (SP, FL/Tax, FL/Doc, FOLFOX) in Patients With Recurrent or Metastatic Gastric Cancer","status":"COMPLETED","sponsor":"Yonsei University","startDate":"2010-03-09","conditions":"Recurrent or Metastatic Gastric Cancer","enrollment":180},{"nctId":"NCT01815307","phase":"PHASE2","title":"Phase II Study of Gemcitabine Versus S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer","status":"COMPLETED","sponsor":"Kansai Hepatobiliary Oncology Group","startDate":"2013-01","conditions":"Biliary Tract Cancer","enrollment":70},{"nctId":"NCT03517618","phase":"PHASE2","title":"TS-1 in Combination With Calcium Folinate in Patients With Heavily Pre-treated mCRC","status":"COMPLETED","sponsor":"TTY Biopharm","startDate":"2014-07-05","conditions":"Metastatic Colorectal Cancer","enrollment":41},{"nctId":"NCT01430052","phase":"PHASE2","title":"Chemoradiotherapy With Gemcitabine/S-1 vs Gemcitabine/S-1 for Locally Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Osaka Medical Center for Cancer and Cardiovascular Diseases","startDate":"2009-04","conditions":"Pancreatic Cancer","enrollment":110},{"nctId":"NCT03316326","phase":"PHASE2","title":"S-1, Irinotecan, and Oxaliplatin in Locally-Advanced Pancreatic Cancer","status":"UNKNOWN","sponsor":"National Taiwan University Hospital","startDate":"2017-11-01","conditions":"Pancreatic Ductal Adenocarcinoma","enrollment":35},{"nctId":"NCT01713387","phase":"PHASE1","title":"A Phase I Study of Adjuvant Chemotherapy With GS in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy","status":"COMPLETED","sponsor":"Kansai Hepatobiliary Oncology Group","startDate":"2012-04","conditions":"Biliary Tract Cancer","enrollment":38},{"nctId":"NCT02527785","phase":"PHASE2","title":"Study of Oxaliplatin, Irinotecan, and S-1 in Gastric Cancer","status":"COMPLETED","sponsor":"Hallym University Medical Center","startDate":"2015-02","conditions":"Stomach Neoplasm","enrollment":44},{"nctId":"NCT01693432","phase":"PHASE2","title":"Docetaxel and S-1 for Advanced Esophageal Cancer","status":"UNKNOWN","sponsor":"Hallym University Medical Center","startDate":"2011-11","conditions":"Esophageal Neoplasms","enrollment":37},{"nctId":"NCT01693419","phase":"PHASE2","title":"S-1, Gemcitabine and Erlotinib for Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Hallym University Medical Center","startDate":"2011-08","conditions":"Pancreas Neoplasms","enrollment":37},{"nctId":"NCT02527824","phase":"PHASE2","title":"Study of Oxaliplatin, Irinotecan, and S-1 in Biliary Tract Cancer","status":"UNKNOWN","sponsor":"Hallym University Medical Center","startDate":"2015-03","conditions":"Biliary Tract Neoplasm","enrollment":31},{"nctId":"NCT03137004","phase":"PHASE2","title":"Docetaxel and S-1 Combination Therapy as Second-line Treatment for Advanced Gastric Cancer","status":"UNKNOWN","sponsor":"Fujian Cancer Hospital","startDate":"2017-06-01","conditions":"Advanced Gastric Cancer","enrollment":47},{"nctId":"NCT01946646","phase":"PHASE1","title":"Phase I Study of TS-1 With Concurrent Radiotherapy to Treat Pancreatic Cancer","status":"TERMINATED","sponsor":"National Taiwan University Hospital","startDate":"2013-10","conditions":"Metastatic Pancreatic Cancer","enrollment":10},{"nctId":"NCT00252161","phase":"PHASE3","title":"A Trial of Neoadjuvant TS-1 and Cisplatin for Type 4 and Large Type 3 Gastric Cancer","status":"COMPLETED","sponsor":"Haruhiko Fukuda","startDate":"2005-11","conditions":"Gastric Neoplasm","enrollment":316},{"nctId":"NCT02870153","phase":"PHASE2","title":"SOX Versus XELOX for Patients With Peritoneal Metastasis of Colorectal Cancer","status":"UNKNOWN","sponsor":"The First People's Hospital of Changzhou","startDate":"2013-01","conditions":"Colorectal Neoplasm","enrollment":60},{"nctId":"NCT00660894","phase":"PHASE3","title":"Tegafur-Uracil and Leucovorin or S-1 in Treating Patients With Stage III Colon Cancer That Has Been Completely Removed by Surgery","status":"COMPLETED","sponsor":"Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan","startDate":"2008-04","conditions":"Colorectal Cancer","enrollment":1535},{"nctId":"NCT01542294","phase":"PHASE1, PHASE2","title":"SOX as Adjuvant Chemotherapy for Resectable Gastric Cancer","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2011-06","conditions":"Gastric Cancer","enrollment":71},{"nctId":"NCT01980810","phase":"PHASE2","title":"First Line Chemotherapy for Advanced Cancer","status":"TERMINATED","sponsor":"Chinese Academy of Medical Sciences","startDate":"2013-09","conditions":"Gastric Cancer","enrollment":36},{"nctId":"NCT01693445","phase":"PHASE1","title":"S-1, Oxaliplatin, and Irinotecan for Advanced Gastrointestinal Cancer","status":"COMPLETED","sponsor":"Hallym University Medical Center","startDate":"2012-06","conditions":"Gastrointestinal Neoplasms","enrollment":22},{"nctId":"NCT01671449","phase":"PHASE3","title":"S-1 and Cisplatin (3 Weekly) Versus S-1 and Oxaliplatin Combination Chemotherapy for Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Min-Hee Ryu","startDate":"2012-12","conditions":"Gastric Cancer","enrollment":338},{"nctId":"NCT01128998","phase":"PHASE1","title":"Sorafenib Plus S-1 in Advanced Solid Tumors","status":"COMPLETED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2009-11","conditions":"Advanced Solid Tumors","enrollment":30},{"nctId":"NCT00438100","phase":"PHASE2","title":"Capecitabine vs. S-1 in Unresectable or Recurrent Breast Cancer","status":"COMPLETED","sponsor":"Japan Breast Cancer Research Network","startDate":"2008-04","conditions":"Breast Neoplasms","enrollment":142},{"nctId":"NCT01679340","phase":"PHASE2","title":"A PhaseⅡ Study: SOX vs SP in Adjuvant Chemotherapy After D2 Surgery","status":"UNKNOWN","sponsor":"Peking University","startDate":"2011-04","conditions":"Gastric Cancer","enrollment":160},{"nctId":"NCT01531452","phase":"PHASE2","title":"The Efficacy of Oxaliplatin Plus S-1 for Treatment of Gastric Cancer","status":"COMPLETED","sponsor":"Chinese Academy of Medical Sciences","startDate":"2011-06","conditions":"Stomach Neoplasms","enrollment":43},{"nctId":"NCT01291615","phase":"PHASE1","title":"Phase I Study of Gemcitabine or S-1 Adjuvant Therapy After Hemihepatectomy for Biliary Tract Cancer","status":"COMPLETED","sponsor":"Kansai Hepatobiliary Oncology Group","startDate":"2010-12","conditions":"Biliary Tract Cancer","enrollment":6},{"nctId":"NCT01284413","phase":"PHASE1, PHASE2","title":"Gemcitabine/Cisplatin/S-1(GCS) Combination Therapy for Patients With Advanced Biliary Tract Cancer","status":"COMPLETED","sponsor":"Kansai Hepatobiliary Oncology Group","startDate":"2010-12","conditions":"Biliary Tract Cancer","enrollment":68},{"nctId":"NCT02146703","phase":"PHASE2","title":"Gemcitabine and S-1 for Advanced Biliary Tract Cancer","status":"COMPLETED","sponsor":"Hallym University Medical Center","startDate":"2005-08","conditions":"Biliary Tract Neoplasm","enrollment":38},{"nctId":"NCT01388790","phase":"PHASE2","title":"Cetuximab in Combination With S-1 and Cisplatin in Gastric Cancer","status":"COMPLETED","sponsor":"Merck KGaA, Darmstadt, Germany","startDate":"2011-06","conditions":"Gastric Cancer","enrollment":40},{"nctId":"NCT00527930","phase":"PHASE2","title":"Phase II Trial of Oxaliplatin in Combination With S-1(SOX) in Patients With Recurrent or Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2007-09","conditions":"Breast Neoplasms","enrollment":87},{"nctId":"NCT01824004","phase":"PHASE2","title":"Postoperative Chemoradiotherapy With S-1 in Gastric Cancer","status":"COMPLETED","sponsor":"Chonnam National University Hospital","startDate":"2009-04","conditions":"Gastric Cancer","enrollment":46},{"nctId":"NCT01747707","phase":"PHASE2","title":"Cisplatin,Docetaxel and S-1 for Advanced Gastric and Gastroesophageal Junction Cancer","status":"UNKNOWN","sponsor":"Chinese Academy of Medical Sciences","startDate":"2012-09","conditions":"Gastric Cancer, Gastroesophageal Junction Cancer","enrollment":40},{"nctId":"NCT00677144","phase":"PHASE2","title":"Oxaliplatin and S-1 (OS) Versus Oxaliplatin and Capecitabine (XELOX) for Advanced Colorectal Cancer","status":"COMPLETED","sponsor":"Hallym University Medical Center","startDate":"2008-04","conditions":"Colorectal Neoplasm","enrollment":88},{"nctId":"NCT00525005","phase":"PHASE2","title":"Docetaxel, Oxaliplatin and S-1 (DOS) for Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Hallym University Medical Center","startDate":"2007-08","conditions":"Stomach Neoplasms","enrollment":44},{"nctId":"NCT01645748","phase":"PHASE2","title":"Docetaxel, Cisplatin, and S-1 (TPS) Induction Chemotherapy in Locally Advanced Head and Neck Cancer","status":"COMPLETED","sponsor":"Chonnam National University Hospital","startDate":"2008-10","conditions":"Head and Neck Cancer","enrollment":35},{"nctId":"NCT01621919","phase":"","title":"Concentration of S-1 Metabolites in Tear and Plasma of Patients Receiving TS-1","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2010-12","conditions":"Gastric Cancer","enrollment":200},{"nctId":"NCT01608646","phase":"PHASE2","title":"Study of DPD for Predicting Efficacy and Safety to S-1 Plus Oxaliplatin in Gastrointestinal Cancer","status":"UNKNOWN","sponsor":"Xijing Hospital","startDate":"2012-03","conditions":"Gastrointestinal Cancer","enrollment":200},{"nctId":"NCT01533324","phase":"PHASE2","title":"S-1/LV One Week on and One Week Off Regimen in Advanced Hepatocellular Carcinoma (HCC)","status":"UNKNOWN","sponsor":"Second Military Medical University","startDate":"2011-11","conditions":"Carcinoma, Liver Diseases, Hepatocellular Carcinoma","enrollment":32},{"nctId":"NCT01131689","phase":"PHASE1","title":"Trial of S-1 in Combination With Sorafenib for Patients With Advanced Hepatocellular Carcinoma","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2009-09","conditions":"Hepatocellular Carcinoma","enrollment":20},{"nctId":"NCT01426646","phase":"PHASE2","title":"S-1 Versus S-1 Plus Cisplatin as an Adjuvant Chemotherapy to Treat Gastric Cancer","status":"UNKNOWN","sponsor":"Kyungpook National University Hospital","startDate":"2011-09","conditions":"Gastric Cancer","enrollment":218},{"nctId":"NCT00659113","phase":"PHASE2","title":"S-1, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIA, Stage III, or Stage IVA Esophageal Cancer That Can Be Removed by Surgery","status":"UNKNOWN","sponsor":"Yonsei University","startDate":"2008-03","conditions":"Esophageal Cancer","enrollment":32},{"nctId":"NCT01429961","phase":"PHASE2","title":"Trial of Palliative Chemotherapy With TS-1 and Oxaliplatin for Patients With Advanced Hepatocellular Carcinoma","status":"UNKNOWN","sponsor":"Seoul National University Hospital","startDate":"2011-05","conditions":"Advanced Hepatocellular Carcinoma","enrollment":38},{"nctId":"NCT00805012","phase":"PHASE2","title":"Docetaxel and S-1 in Head and Neck Squamous Cell Carcinoma (HNSCC)","status":"TERMINATED","sponsor":"Seoul National University Hospital","startDate":"2008-12","conditions":"Head and Neck Squamous Cell Carcinoma","enrollment":96},{"nctId":"NCT00152217","phase":"PHASE3","title":"Adjuvant Chemotherapy Trial of TS-1 for Gastric Cancer (ACTS-GC)","status":"COMPLETED","sponsor":"Taiho Pharmaceutical Co., Ltd.","startDate":"2001-09","conditions":"Gastric Cancer","enrollment":1000},{"nctId":"NCT00287768","phase":"PHASE3","title":"Phase III Study of Docetaxel + S-1 vs. S-1 for Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Japan Clinical Cancer Research Organization","startDate":"2006-03","conditions":"Gastric Cancer","enrollment":628},{"nctId":"NCT00514163","phase":"PHASE2","title":"GEM vs GEM+TS-1 for Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Japan Clinical Cancer Research Organization","startDate":"2007-06","conditions":"Pancreatic Cancer","enrollment":110},{"nctId":"NCT00639327","phase":"PHASE2, PHASE3","title":"Second Line Chemotherapy for S-1 Refractory Advanced Gastric Cancer","status":"COMPLETED","sponsor":"Japan Clinical Cancer Research Organization","startDate":"2008-03","conditions":"Gastric Cancer","enrollment":300},{"nctId":"NCT01096745","phase":"PHASE2","title":"Randomized Trial of Gemcitabine/Cisplatin Versus S-1/Cisplatin in Advanced Biliary Cancer","status":"TERMINATED","sponsor":"Gyeongsang National University Hospital","startDate":"2010-07","conditions":"Metastatic Biliary Tract Cancer, Locally Advanced Biliary Tract Cancer","enrollment":78},{"nctId":"NCT00960349","phase":"PHASE1","title":"Study of Cediranib Plus Cisplatin Plus Capecitabine/S-1 in Japanese Gastric Cancer Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2009-08","conditions":"Gastric Cancer","enrollment":14},{"nctId":"NCT00874328","phase":"PHASE1, PHASE2","title":"A Study of TS-1 Plus Irinotecan and Cisplatin (IP) for Patients With Stage IIIB/IV Non Small Cell Lung Cancer (NSCLC)","status":"UNKNOWN","sponsor":"National Cancer Center, Korea","startDate":"2008-10","conditions":"Advanced Non-Small Cell Lung Cancer","enrollment":74},{"nctId":"NCT00209729","phase":"PHASE1, PHASE2","title":"Phase I/II Study of Oral S-1 Plus Docetaxel in Elderly Patients With Advanced Gastric Cancer.","status":"SUSPENDED","sponsor":"Hokkaido Gastrointestinal Cancer Study Group","startDate":"2005-04","conditions":"Gastric Cancer","enrollment":50},{"nctId":"NCT00512681","phase":"PHASE2","title":"A Phase II Study of Irinotecan, Oxaliplatin, Plus TS-1 in Untreated Metastatic Gastric Cancer","status":"COMPLETED","sponsor":"National Cancer Center, Korea","startDate":"2007-07","conditions":"Stomach Neoplasms","enrollment":44},{"nctId":"NCT00961077","phase":"PHASE2","title":"Attenuated SOX as First-line Treatment in Elderly Patients With Relapsed or Metastatic Gastric Cancer","status":"UNKNOWN","sponsor":"Soonchunhyang University Hospital","startDate":"2009-08","conditions":"Elderly, S-1, Oxaliplatin","enrollment":36},{"nctId":"NCT00503321","phase":"PHASE2, PHASE3","title":"Phase II Study of TS-1 Therapy and TS-1+PSK Therapy Against Advanced Gastric Carcinoma","status":"TERMINATED","sponsor":"Eastern Network of Cancer Immunological Therapy, Japan","startDate":"2006-10","conditions":"Gastric Cancer","enrollment":13},{"nctId":"NCT00316745","phase":"PHASE3","title":"IRIS Followed by mFOLFOX6 or the Reverse Sequence in Advanced Colorectal Cancer","status":"SUSPENDED","sponsor":"Hokkaido Gastrointestinal Cancer Study Group","startDate":"2006-04","conditions":"Metastatic Colorectal Cancer","enrollment":200},{"nctId":"NCT00209651","phase":"PHASE2","title":"Phase II Study of Oral S-1 Plus Irinotecan (IRIS) in Patients With Advanced Colorectal Cancer","status":"UNKNOWN","sponsor":"Hokkaido Gastrointestinal Cancer Study Group","startDate":"2004-01","conditions":"Colorectal Cancer","enrollment":40},{"nctId":"NCT00506571","phase":"PHASE2","title":"Phase II Study of Irinotecan,Oxaliplatin Plus TS-1 in Untreated Metastatic Colorectal Cancer","status":"UNKNOWN","sponsor":"National Cancer Center, Korea","startDate":"2007-07","conditions":"Colorecal Neoplasms, Secondary","enrollment":42}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["S-1"],"phase":"phase_3","status":"active","brandName":"TS-1 (S-1)","genericName":"TS-1 (S-1)","companyName":"National Cancer Center, Korea","companyId":"national-cancer-center-korea","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TS-1 is a medication used to treat Recurrent or Metastatic Gastric Cancer, Gastric Cancer, Advanced Non-Small Cell Lung Cancer, and Biliary Tract Neoplasm. It is administered as part of treatment regimens including SP, FL/Tax, and FL/Doc.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}